Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors
This study has been completed.
Sponsor:
Sunesis Pharmaceuticals
Information provided by:
Sunesis Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00519662
First received: August 20, 2007
Last updated: March 5, 2009
Last verified: March 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.
| Condition | Intervention | Phase |
|---|---|---|
|
Advanced Solid Tumors |
Drug: SNS-314 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 1 Open-Label Multicenter, Dose-Escalating, Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of SNS-314, a Novel Aurora Kinase Inhibitor, Administered to Patients With Advanced Solid Tumors |
Further study details as provided by Sunesis Pharmaceuticals:
Primary Outcome Measures:
- To assess the safety and tolerability of SNS-314 [ Time Frame: 1 Year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 50 |
| Study Start Date: | August 2007 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: SNS-314
Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15 Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1 |
Detailed Description:
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Advanced solid tumor and that is measurable by a scan
Exclusion Criteria:
- Uncontrolled or untreated central nervous system metastases
- Cerebrovascular accident/transient ischemic attack up to 6 months before Cycle 1 Day 1
- Any of the following cardiac conditions:
- History of myocardial infarction, acute coronary syndromes up to 12 weeks before Cycle 1 Day 1
- Class III or IV heart failure up to 6 months before Cycle 1 Day 1
- Baseline heart rate corrected QT interval (QTc)> 450 msec
- History of ventricular arrhythmias up to 6 months before Cycle 1 Day 1
- Use of medications that prolong the QTc interval and are associated with Torsades de Pointe (TdP)
- Previous cancer treatment up to 21 days before first dose
- Any investigational therapy up to 28 days before Cycle 1 Day 1
- Known allergy to cyclodextrins
Please note: There are additional inclusion/exclusion criteria for this study. Please contact the study center for additional information and to determine if all study criteria are met.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00519662
Please refer to this study by its ClinicalTrials.gov identifier: NCT00519662
Locations
| United States, Alabama | |
| University of Alabama, Birmingham | |
| Birmingham, Alabama, United States, 35233 | |
| United States, California | |
| Stanford University Medical Center | |
| Stanford, California, United States, 94305 | |
| United States, New Mexico | |
| University of New Mexico | |
| Albuquerque, New Mexico, United States, 87131 | |
| United States, North Carolina | |
| Duke University | |
| Durham, North Carolina, United States, 27710 | |
Sponsors and Collaborators
Sunesis Pharmaceuticals
Investigators
| Study Director: | Glenn Michelson, MD | Sunesis Pharmaceuticals |
More Information
No publications provided
| Responsible Party: | Glenn Michelson, MD, Sunesis Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00519662 History of Changes |
| Other Study ID Numbers: | SPO-0011 |
| Study First Received: | August 20, 2007 |
| Last Updated: | March 5, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Sunesis Pharmaceuticals:
|
Solid Tumors Advanced |
ClinicalTrials.gov processed this record on March 01, 2015